Please note a correction to the financial calendar. The Annual Report will be published 4 April 2016.

Publication date Notes
4 April 2016 Annual Report 2015
28 April 2016 Annual General Meeting
29 April 2016 Minutes from Annual General Meeting
13 May 2016 Q1 2016 Report
26 August 2016 Half Year 2016 Report
11 November 2016 Q3 2016 Report

Serendex reserves the right to make changes to the content and dates displayed in this message. The information is also available at our website under Investor Relations / Financial Calendar.

For further information, please contact:

Nadia Vega Vasiljev
Head of Communication and IR
Mobile +45 2014 9615
E-mail: nvv@serendex.com

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess. Please visitwww.serendex.com to learn more.

Serendex Pharmaceuticals A/S issued this content on 19 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 February 2016 08:20:24 UTC

Original Document: http://www.serendex.com/correction-to-serendex-financial-calendar-2016-2/